%0 Journal Article %A TAKAHIRO YAMAUCHI %A EIJU NEGORO %A SHIN LEE %A MIHOKO TAKAI %A YASUFUMI MATSUDA %A KAZUTAKA TAKAGI %A SHINJI KISHI %A KATSUNORI TAI %A NAOKO HOSONO %A TOSHIKI TASAKI %A SATOSHI IKEGAYA %A KUNIHIRO INAI %A AKIRA YOSHIDA %A YOSHIMASA URASAKI %A HIROMICHI IWASAKI %A TAKANORI UEDA %T A High Serum Uric Acid Level Is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia %D 2013 %J Anticancer Research %P 3947-3951 %V 33 %N 9 %X Uric acid in serum (S-UA) is produced by the breakdown of the cellular nucleic acids of leukemia cells, and may be a marker of disease aggressiveness. S-UA levels were examined for association with clinical outcomes in patients with acute myeloid leukemia (AML). Fifty-six patients with AML admitted to our Institution were evaluated retrospectively. The median S-UA level at diagnosis was 5.0 mg/dl (range 2-13.8 mg/dl). The S-UA levels did not correlate with peripheral lactate dehydrogenase, peripheral white blood cell counts, or peripheral blast counts, and were not proportional to bone marrow blast counts or marrow cellularity. The S-UA levels in the patients who achieved complete remission were slightly lower than those in those who did not. S-UA levels less than, or equal to the median (5.0 mg/dl) were significantly associated with better prognoses, compared with S-UA levels greater than 5.0 mg/dl. Thus, the S-UA level may predict the prognosis of AML, and is a versatile and cost-effective test for such a purpose. %U https://ar.iiarjournals.org/content/anticanres/33/9/3947.full.pdf